{"title": "Clinical Cell and Vaccine Production Facility (CVPF)", "author": null, "url": null, "hostname": null, "description": null, "sitename": null, "date": "2015-10-11", "cleaned_text": "| | - [Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia.](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/34156874/__;!!IBzWLUs!EVWc_kB0su7q6W0EaT08RwC96dNkpVtGcqzLOrCfb1KZH5VqCk0N16YFfg_BrsWe$) Myers RM, Li Y, Barz Leahy A, Barrett DM, Teachey DT, Callahan C, Fasano Rheingold SR, DiNofia A, Wray L, Aplenc R, E, Getz KD, Brogdon JL, Fesnak AD, MM, Bartoszek C, Lacey SF, Hexner EO, Chew A, Wertheim GB, Levine BL, June CH, bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia.](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/34396987/__;!!IBzWLUs!EVWc_kB0su7q6W0EaT08RwC96dNkpVtGcqzLOrCfb1KZH5VqCk0N16YFfp6ZGajs$)Kong W, Dimitri A, Wang W, Jung IY, Ott CJ, Fasolino M, Wang Y, Kulikovskaya I, Gupta M, Yoder T, DeNizio JE, Everett JK, Williams EF, Xu J, Scholler J, Reich TJ, Bhoj VG, Haines KM, Maus JJ, June CH, Davis MM, Lacey SF, T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy.](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/33713436/__;!!IBzWLUs!EVWc_kB0su7q6W0EaT08RwC96dNkpVtGcqzLOrCfb1KZH5VqCk0N16YFfnFq6JGM$)Bernabei L, Tian L, Garfall AL, Melenhorst JJ, Lacey SF, Stadtmauer EA, Vogl DT, Gonzalez VE, Plesa G, Young RM, A, Levine BL, Program T cells augment HIV-specific immunity to enable post-rebound control of HIV replication.](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/33571163/__;!!IBzWLUs!EVWc_kB0su7q6W0EaT08RwC96dNkpVtGcqzLOrCfb1KZH5VqCk0N16YFfoLplTBA$)Tebas P, Jadlowsky JK, Shaw PA, Tian L, Esparza E, Brennan AL, Kim S, Naing SY, Richardson MW, Vogel AN, Maldini CR, Kong H, Liu X, Lacey SF, Bauer AM, Mampe F, Richman LP, Lee G, Ando D, Levine BL, Porter DL, Zhao Y, Siegel DL, Bar KJ, June CH, Riley H, Lee DH, Kulikovskaya I, Bartoszek C, F, L, Mesothelin and CD19 with Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer.](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/32730744/__;!!IBzWLUs!EVWc_kB0su7q6W0EaT08RwC96dNkpVtGcqzLOrCfb1KZH5VqCk0N16YFfndokx6-$)Ko AH, Jordan AC, Tooker E, Lacey SF, Chang RB, Li Y, Venook AP, Tempero M, Damon L, Fong L, O'Hara MH, Levine BL, Melenhorst JJ, Plesa G, 32730744 - Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia.](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/32298202/__;!!IBzWLUs!EVWc_kB0su7q6W0EaT08RwC96dNkpVtGcqzLOrCfb1KZH5VqCk0N16YFfr9EZ410$)Frey NV, Gill S, Hexner EO, Schuster A, Landsburg SF, Melenhorst JJ, Veloso E, Gaymon A, Pequignot E, Shan X, Hwang WT, June CH, Clin 32298202 Clinical cells in patients with refractory cancer.](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/32029687/__;!!IBzWLUs!EVWc_kB0su7q6W0EaT08RwC96dNkpVtGcqzLOrCfb1KZH5VqCk0N16YFftT6iw35$)Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, Plesa G, Shea J, Matlawski AL, Desjardins S, Lamontagne J, Fesnak A, Siegel DL, Levine BL, Jadlowsky JK, RM, AT, Chang HY, Zhao Y, Lacey SF, June CH. Science. 2020 Feb 28;367(6481):eaba7365. doi: 10.1126/science.aba7365. Epub 2020 Feb 6.PMID: 32029687 Clinical Trial. long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting genomic modification by vector integration.](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/31845905/__;!!IBzWLUs!EVWc_kB0su7q6W0EaT08RwC96dNkpVtGcqzLOrCfb1KZH5VqCk0N16YFfrNX01UN$)Nobles CL, Sherrill-Mix S, Everett JK, Reddy S, Fraietta JA, Porter DL, Frey N, Gill SI, Grupp SA, Maude SL, Siegel DL, Levine BL, June CH, Lacey SF, Melenhorst JJ, Clinical Trial. - [Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia.](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/31815579/__;!!IBzWLUs!EVWc_kB0su7q6W0EaT08RwC96dNkpVtGcqzLOrCfb1KZH5VqCk0N16YFfm_y2gf-$)Frey NV, Shaw Hexner Perl AE, Maude SL, Grupp SA, Shah NN, Gilmore J, Lacey SF, Melenhorst JJ, Levine BL, June CH, Porter Trial. - [T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma.](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/31575532/__;!!IBzWLUs!EVWc_kB0su7q6W0EaT08RwC96dNkpVtGcqzLOrCfb1KZH5VqCk0N16YFfi_93hh4$)Garfall AL, Dancy EK, Cohen AD, Hwang WT, Fraietta MM, Levine BL, Siegel DL, PMC article. - [CAR T cell viability release testing and clinical outcomes: is there a lower limit?](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/31554634/__;!!IBzWLUs!EVWc_kB0su7q6W0EaT08RwC96dNkpVtGcqzLOrCfb1KZH5VqCk0N16YFfhBVDi4N$)Chong EA, Levine BL, Grupp SA, Davis MM, Siegel DL, Maude SL, Gladney WL, Frey NV, Porter DL, Hwang WT, Chong ER, June CH, Schuster S J.Blood. 2019 Nov 21;134(21):1873-1875. doi: 10.1182/blood.2019002258.PMID: 31554634 Free PMC article. abstract [Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Cancers.](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/31420241/__;!!IBzWLUs!EVWc_kB0su7q6W0EaT08RwC96dNkpVtGcqzLOrCfb1KZH5VqCk0N16YFfiYNLFIY$)Haas AR, Tanyi JL, MC, Tian L, McGarvey M, Nelson AM, Farabaugh CS, Moon E, Levine BL, Clinical Trial. - [B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/30896447/__;!!IBzWLUs!EVWc_kB0su7q6W0EaT08RwC96dNkpVtGcqzLOrCfb1KZH5VqCk0N16YFflDVZkeD$) Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, Vogl DT, Weiss BM, Dengel K, Nelson A, Plesa G, Chen F, Davis MM, Hwang WT, Young RM, Brogdon JL, Isaacs R, PMC article. Clinical Trial. Kinetic Analysis of Chimeric Antigen Receptor-T Cells.](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/30848084/__;!!IBzWLUs!EVWc_kB0su7q6W0EaT08RwC96dNkpVtGcqzLOrCfb1KZH5VqCk0N16YFfqTEdmhY$)Stein AM, Grupp SA, Levine JE, Boyer MW, August KJ, Levine BL, Tomassian L, Shah S, Leung M, Huang PH, Awasthi KT, - [Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell.](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/30275568/__;!!IBzWLUs!EVWc_kB0su7q6W0EaT08RwC96dNkpVtGcqzLOrCfb1KZH5VqCk0N16YFfg5-FkSY$)Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, PR, Kulikovskaya I, Nazimuddin F, Bhoj VG, Orlando EJ, Fry TJ, H, Maude SL, Levine BL, Nobles CL, Bushman FD, Young RM, Scholler J, Gill June CH, Grupp SA, Lacey J J.Nat MA, Boyer MW, August KJ, Hamilton J, Awasthi R, Stein AM, Sickert D, Chakraborty A, Levine BL, June CH, Tomassian L, Shah SS, Leung M, Taran T, Wood PA, Maude SL.Clin Cancer Res. 2018 Dec doi: 10.1158/1078-0432.CCR-18-0758. [Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma.](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/29925499/__;!!IBzWLUs!EVWc_kB0su7q6W0EaT08RwC96dNkpVtGcqzLOrCfb1KZH5VqCk0N16YFfjjPr-4J$) Svoboda J, Rheingold SR, Gill SI, Grupp SA, Lacey SF, Kulikovskaya I, Suhoski MM, Melenhorst B, SD, DJ, Youngman MR, Levine BL, Porter DL, S doi: Clinical Trial. [Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells.](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/29849141/__;!!IBzWLUs!EVWc_kB0su7q6W0EaT08RwC96dNkpVtGcqzLOrCfb1KZH5VqCk0N16YFfkI45mcA$)Fraietta JA, Nobles CL, Sammons MA, Lundh TJ, Cogdill Morrissette JJD, DeNizio JE, Reddy S, Hwang Y, Gohil M, Kulikovskaya I, Nazimuddin F, Gupta M, Chen F, Everett JK, Alexander KA, Lin-Shiao E, Gee MH, Liu X, Young RM, Ambrose D, Wang Y, Xu J, Jordan MS, Marcucci KT, Levine BL, Garcia KC, Zhao Y, Kalos M, Porter DL, Kohli RM, Lacey SF, Berger SL, [Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/29713085/__;!!IBzWLUs!EVWc_kB0su7q6W0EaT08RwC96dNkpVtGcqzLOrCfb1KZH5VqCk0N16YFfmp9cevm$)Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O'Connor RS, Hwang WT, Pequignot E, Ambrose DE, Zhang C, Wilcox N, Bedoya F, Dorfmeier C, Chen F, Tian L, Parakandi H, Gupta M, Young RM, Johnson FB, Kulikovskaya I, Liu L, Xu J, Kassim SH, Davis MM, Levine BL, Frey NV, Siegel DL, Huang AC, Wherry EJ, Bitter H, Brogdon JL, Porter CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory Stadtmauer EA, Hwang WT, MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, 2018 29669947 Free PMC Clinical Trial. - [Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/29643231/__;!!IBzWLUs!EVWc_kB0su7q6W0EaT08RwC96dNkpVtGcqzLOrCfb1KZH5VqCk0N16YFfjw6gKn_$)Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti Baumgartner P, Stevenson C, Dangaj B, Semilietof A, Racle Michel A, C, DS, DA, Nisenbaum HL, O, DJ Jr, Gfeller D, Mick R, Dafni U, Zoete V, Harari A, T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial.](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/29567081/__;!!IBzWLUs!EVWc_kB0su7q6W0EaT08RwC96dNkpVtGcqzLOrCfb1KZH5VqCk0N16YFfvjAO2we$)Beatty GL, O'Hara MH, Lacey SF, Torigian DA, Nazimuddin F, Chen F, Kulikovskaya IM, PMC article. Clinical Trial. - [Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia](https://www.nejm.org/doi/10.1056/NEJMoa1709866)Maude SL, Laetsch TW, Buechner J, Rives M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose Hiramatsu Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, F, Balduzzi A, Krueger J, June CH, BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA.. N Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines. ](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/28470889/__;!!IBzWLUs!BaQ3Cp0fhYTXGBhK0jqHaofo1Du-L-YOW7DLwX5YJIkk8DGnT17yfBxhvwsc-O49$)Hippen KL, O'Connor RS, JL, Levine BL, June CH, Turka LA, Kean LS, MacMillan ML, Miller JS, Wagner JE, Munn DH, Blazar Hofmann TJ, Gershenson Production of refueling CAR. ](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/28031179/__;!!IBzWLUs!BaQ3Cp0fhYTXGBhK0jqHaofo1Du-L-YOW7DLwX5YJIkk8DGnT17yfBxhv1luVS6Y$) Chong EA, Melenhorst JJ, Lacey SF, Ambrose DE, Gonzalez V, Levine purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials. ](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/27887864/__;!!IBzWLUs!BaQ3Cp0fhYTXGBhK0jqHaofo1Du-L-YOW7DLwX5YJIkk8DGnT17yfBxhv3mh-YKC$)McKenna Jr, Sumstad AL, W, Ni X, Ranganathan P, Levine BL, Riley JL, June CH, Turka LA, Munn DH, Garzon Blood. 2016 10.1182/blood-2016-05-714535. Epub Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. ](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/27076371/__;!!IBzWLUs!BaQ3Cp0fhYTXGBhK0jqHaofo1Du-L-YOW7DLwX5YJIkk8DGnT17yfBxhvw-sabao$)Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, Pequignot E, Gonzalez VE, Chen F, Finklestein J, Barrett DM, Weiss SL, Fitzgerald JC, Berg RA, Aplenc R, Callahan C, Rheingold SR, Zheng Z, Rose-John S, White JC, Nazimuddin F, Wertheim G, Levine BL, June CH, Porter SA. CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment. ](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/26858124/__;!!IBzWLUs!BaQ3Cp0fhYTXGBhK0jqHaofo1Du-L-YOW7DLwX5YJIkk8DGnT17yfBxhvwEuzAiK$)Hexner EO, Luger SM, Reshef Richman LP, Vonderheide RH, Aqui NA, Rosenbach M, AW, Stadtmauer EA, Levine BL, June CH, Emerson J Hematol. May;91(5):453-60. doi: 10.1002/ajh.24303. Epub 2016 Apr 4. PMID: 26858124. Clinical Trial. - [Novel gene and cellular therapy approaches for treating HIV. ](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/27232514/__;!!IBzWLUs!BaQ3Cp0fhYTXGBhK0jqHaofo1Du-L-YOW7DLwX5YJIkk8DGnT17yfBxhvzRwxrf5$)Bhoj VG, Thibodeaux SR, Levine engraftment and efficacy in leukemia. ](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/26813675/__;!!IBzWLUs!BaQ3Cp0fhYTXGBhK0jqHaofo1Du-L-YOW7DLwX5YJIkk8DGnT17yfBxhv8N4M4A2$) Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, Lacey SF, Melenhorst JJ, McGettigan SE, Cook DR, Zhang C, Xu J, Do P, Hulitt J, Kudchodkar SB, Cogdill AP, Gill S, Porter DL, Woyach JA, Long M, Johnson AJ, Maddocks K, Muthusamy N, Levine BL, June CH, Byrd MV. Blood. 2016 doi: 10.1182/blood-2015-11-679134. Epub 26. PMID: 26813675 - [Smart CARS: optimized development of a chimeric antigen receptor (CAR) T cell targeting epidermal growth factor receptor variant III (EGFRvIII) for glioblastoma. ](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/26855949/__;!!IBzWLUs!BaQ3Cp0fhYTXGBhK0jqHaofo1Du-L-YOW7DLwX5YJIkk8DGnT17yfBxhv4wPMHgh$) PMID: abstract available. - [Phase I study of multi-gene cell therapy in patients with peripheral artery disease. ](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/26584888/__;!!IBzWLUs!BaQ3Cp0fhYTXGBhK0jqHaofo1Du-L-YOW7DLwX5YJIkk8DGnT17yfBxhvzIZW540$) Grossman PM, Mohler ER 3rd, Roessler BJ, B, 26584888. Clinical Trial. - [Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical Levine BL, Riley JL, June CH, Le C, Weisdorf DJ, McGlave PB, Blazar Wagner JE. Blood. 2016 25;127(8):1044-51. doi: 10.1182/blood-2015-06-653667. Epub 2015 Nov 12. PMID: 26563133. Clinical Trial. - [T cell engineering as therapy for cancer and HIV: our synthetic future. ](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/26416683/__;!!IBzWLUs!BaQ3Cp0fhYTXGBhK0jqHaofo1Du-L-YOW7DLwX5YJIkk8DGnT17yfBxhv16SGPir$) June CH, Levine BL. Philos Trans R doi: 10.1098/rstb.2014.0374. PMID: 26416683. Review. - [Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. ](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/26333935/__;!!IBzWLUs!BaQ3Cp0fhYTXGBhK0jqHaofo1Du-L-YOW7DLwX5YJIkk8DGnT17yfBxhv7csZdM4$) Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V, Ambrose D, Grupp SA, Chew A, Zheng Z, Milone MC, Levine BL, Melenhorst JJ, B, Finklestein J, Kulikovskaya I, Sinha SK, Kronsberg S, Gupta M, Bond S, Melchiori L, Brewer JE, Bennett AD, Gerry AB, Pumphrey NJ, Williams D, Tayton-Martin HK, Ribeiro L, Holdich T, Yanovich S, Hardy N, Yared J, Kerr N, Philip S, Westphal S, Siegel DL, Levine BL, Jakobsen BK, Kalos CH. Nat PMID: 26193344 Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy. ](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/25712684/__;!!IBzWLUs!BaQ3Cp0fhYTXGBhK0jqHaofo1Du-L-YOW7DLwX5YJIkk8DGnT17yfBxhv0yQQx2U$)Zsiros E, Duttagupta P, Dangaj D, Li H, Frank R, Garrabrant T, Hagemann IS, Levine BL, June CH, Zhang L, Wang E, Marincola FM, Bedognetti D, Powell DJ Jr, Tanyi J, Feldman MD, Kandalaft LE, Coukos G. Clin Cancer Res. 2015 2015 Feb 23. PMID: 25712684 - [Chimeric antigen receptor T cells for sustained remissions in leukemia. ](https://urldefense.com/v3/__https:/pubmed.ncbi.nlm.nih.gov/25317870/__;!!IBzWLUs!BaQ3Cp0fhYTXGBhK0jqHaofo1Du-L-YOW7DLwX5YJIkk8DGnT17yfBxhv3ybwuFE$) Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA. 2014 16;371(16):1507-17. 14;316(3):38-43. doi: 10.1038/scientificamerican0317-38. PMID: 28207696 No abstract available. "}